Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863990 | 1.00 | SLC6A3 (0.33) | SLC6A3ELANECYP19A1ESR1ALOX15 | |
| SCHEMBL3863989 | 1.00 | SLC6A3 (0.33) | SLC6A3ELANECYP19A1ESR1ALOX15 | |
| SCHEMBL3867893 | 1.00 | SLC6A3 (0.33) | SLC6A3ELANECYP19A1ESR1ALOX15 | |
| SCHEMBL3863992 | 1.00 | SLC6A3 (0.33) | SLC6A3ELANECYP19A1ESR1ALOX15 | |
| SCHEMBL3867892 | 1.00 | SLC6A3 (0.33) | SLC6A3ELANECYP19A1ESR1ALOX15 | |
| SCHEMBL3861844 | 0.83 | SLC6A3 (0.37) | SLC6A3KMT2AEPHX1EPHX2 | |
| SCHEMBL3861842 | 0.83 | SLC6A3 (0.37) | SLC6A3KMT2AEPHX1EPHX2 | |
| SCHEMBL3861847 | 0.83 | SLC6A3 (0.37) | SLC6A3KMT2AEPHX1EPHX2 | |
| SCHEMBL5191282 | 0.82 | ESR1 (0.39) | SLC6A3ESR1KMT2A | |
| SCHEMBL3758703 | 0.82 | ESR1 (0.39) | SLC6A3ESR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1845078-B1 | PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR | TAKASAGO PERFUMERY CO LTD (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-7479574-B2 | Method of producing macrocyclic ketone, and intermediate thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1845078-A1 | PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR | Takasago International Corporation (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | MSMO1, CYP17A1, DNMT1 | SLC6A3 1984/4885ELANE 3903/4885CYP19A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.